Affinity Investment Advisors, LLC Allogene Therapeutics, Inc. Transaction History

Affinity Investment Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 05, 2022	SELL	$7.65 - $15.29 $192,848 - $385,445	-25,209 Closed	0 $0
Q4 2021 Feb 04, 2022	SELL	$13.13 - $24.52 $56,498 - $105,509	-4,303 Reduced 14.58%	25,209 $376,000
Q3 2021 Nov 08, 2021	SELL	$21.01 - $27.64 $5,147 - $6,771	-245 Reduced 0.82%	29,512 $758,000
Q2 2021 Aug 09, 2021	BUY	$23.49 - $35.8 $171,007 - $260,623	7,280 Added 32.39%	29,757 $776,000
Q1 2021 May 13, 2021	BUY	$25.79 - $39.02 $3,842 - $5,813	149 Added 0.67%	22,477 $793,000
Q4 2020 Feb 12, 2021	BUY	$25.24 - $43.45 $52,650 - $90,636	2,086 Added 10.31%	22,328 $564,000
Q3 2020 Nov 13, 2020	BUY	$32.38 - $44.96 $655,435 - $910,080	20,242 New	20,242 $763,000

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Affinity Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Investment Advisors, LLC with notifications on news.